TABLE 6:
Progression-Free Survival | Disease Specific Survival | ||||||
---|---|---|---|---|---|---|---|
1-year | 5-year | p* | 1-year | 5-year | p* | ||
S100 | Positive | 65% | 22% | 0.31 | 85% | 33% | 0.463 |
Negative | 47% | 13% | 8 | 71% | 31% | ||
SOX10 | Positive | 66% | 35% | 0.37 | 83% | 46% | 0.495 |
Negative | 53% | 14% | 2 | 74% | 29% | ||
Neurofibromin | Positive | 55% | 29% | 0.43 | 83% | 22% | 0.019 |
Negative | 37% | NA | 70% | 15% | |||
p16 | Positive | 68% | 36% | 0.21 | 83% | 44% | 0.185 |
Negative | 51% | 11% | 8 | 74% | 30% | ||
EGFR | Positive | 40% | 22% | 0.22 | 75% | 25% | 0.2 |
Negative | 67% | 18% | 8 | 77% | 36% | ||
p75NTR | Positive | 47% | 29% | 0.98 | 76% | 25% | 0.897 |
Negative | 50% | NA | 1 | 75% | 19% | ||
SOX2 | Positive | 54% | 22% | 0.50 | 74% | 32% | 0.421 |
7 | |||||||
Negative | 61% | NA | 89% | 32% | |||
p53 | Positive | 56% | 27% | 0.25 | 81% | 26% | 0.246 |
5 | |||||||
Negative | 17% | NA | 60% | NA | |||
Ki67, % | <20 | 80% | NA | 0.19 | 80% | NA | 0.048 |
9 | |||||||
≥20 | 43% | 21% | 74% | 9% |
All p values were calculated from Kaplan-Meier analysis by Log-rank method, and p values in bold are significant; NA: Not available, all cases were censored.